Idioma:

Clinical pharmacology of the apixaban and frequently asked questions about its clinical use

Abacı, Adnan

Türk Kardiyoloji Derneği arşivi, 2016-09, Vol.44, p.Supplement 1 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Clinical pharmacology of the apixaban and frequently asked questions about its clinical use
Autor: Abacı, Adnan
Assuntos: Inhibitor drugs ; Pharmacology ; Thromboembolism
É parte de: Türk Kardiyoloji Derneği arşivi, 2016-09, Vol.44, p.Supplement 1
Descrição: Apixaban is a new, strong, reversible, competitive direct inhibitor of factor Xa. By inhibiting factor Xa, it prevents the conversion of prothrombin to thrombin. Large, randomized clinical trials showed that apixaban is superior to varfarin in the prevention of stroke in atrial fibrillation and caused less bleeding than varfarin. This article summarized clinical pharmacology of the apixaban and responded to frequently asked questions about it.
Editor: Istanbul: Aves Yayincilik Ltd. STI
Idioma: Inglês

Voltar para lista de resultados